Blood Donor Recruitment During Epidemic of COVID-19

Status Completed

Clinical Trial Summary

In December 2019, an unknown pneumonia rapidly spread in Wuhan, China, a new coronavirus, 2019 novel coronavirus (2019-nCoV), aroused the attention of the entire world. On January 31, 2020, World Health Organization (WHO) announced the outbreak of Coronavirus Disease 2019 (COVID-19) in China as a Public Health Emergency of International Concern. The number of volunteer non-remunerated blood donors decreased because of quarantine, caring for relatives, and fear of exposure to COVID-19. Due to the blood shortage, patient blood management and cessation of elective surgery are contributing to decreased demand, but sepsis may increase requirements and significant reductions will not be possible in areas such as trauma, cancer patients, hereditary haemolytic anaemias and childbirth. Therefore, recruiting enough blood donors during the epidemic is vital for public health in China, and also worldwide. In order to assess the effects of a questionnaire on blood donor recruitment, the investigators designed two kinds of self-administered, standardized and structured questionnaires. In addition of the basic socio-demographic characteristics, one questionnaire includes the information of precautions of blood donation during epidemic, and the other dose not. The questionnaires were randomly sent to ever blood donors, and the same number of ever blood donors are coded as control.

Clinical Trial Description

In order to assess the effects of a questionnaire on blood donor recruitment, the investigators designed two kinds of self-administered, standardized and structured questionnaires. In addition of the basic socio-demographic characteristics, one questionnaire includes the information of precautions of blood donation during epidemic, and the other dose not.

Information of precautions of blood donation during epidemic included taking donor's temperature and enhancing hand disinfection before donation etc.

The questionnaires were randomly sent to ever blood donors, and at the same day, equal number of ever blood donors as the ones who filled the questionnaire are coded as control. ;

Study Design

Related Conditions & MeSH terms

Blood Donation

Clinical Trial Details

NCT number	NCT04306055
Study type	Interventional
Source	Guangzhou Blood Center
Contact
Status	Completed
Phase	N/A
Start date	March 13, 2020
Completion date	April 3, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05791968` - Blood Donation Could Improve Insulin Sensitivity	N/A
Recruiting	`NCT02281565` - Attitudes About Blood Donation	N/A
Enrolling by invitation	`NCT04410458` - Recruit Blood Donors Via SMS During Epidemic of COVID-19 （Repeat Trial）	N/A
Active, not recruiting	`NCT01610635` - INTERVAL Study: To Determine Whether the Interval Between Blood Donations in England Can be Safely and Acceptably Decreased	N/A
Enrolling by invitation	`NCT04431180` - Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial#	N/A
Recruiting	`NCT04484896` - Message Framing on Recruiting Rh-D Negative Blood Donors	N/A
Active, not recruiting	`NCT05678647` - Sucrosomial Iron and Iron Sulphate to Blood Donors	N/A
Completed	`NCT05319951` - Effect of Different Liquids Intake in Vasovagal Reaction After Whole Blood Donation	N/A
Completed	`NCT05213130` - Blood Donation and Subjective Well-being	N/A
Completed	`NCT00023023` - Study of Transfusion-Transmitted Infections
Recruiting	`NCT06101238` - BLOODSAFE Ghana- Iron and Nutritional Counselling Strategy	N/A
Enrolling by invitation	`NCT06138899` - Enhancing Blood Donation at Schools and Beyond in Malawi	N/A
Completed	`NCT04370886` - Recruit Blood Donors Via SMS During Epidemic of COVID-19	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.